Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuron Ltd Regulatory Filings 2018

Mar 16, 2018

35121_ffr_2018-03-16_0a82f2fa-1b8c-4d53-bf8d-3868a725107d.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

6-K 1 s109380_6k.htm 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2018

Commission File Number: 001-38104

IMMURON LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Field: Page; Sequence: 1

Field: /Page

IMMURON LIMITED

EXPLANATORY NOTE

Immuron Limited (the “Company”) published an announcement (the “Public Notice”) to the Australian Securities Exchange on March 16, 2018 titled “Appendix 3B & 708A Notice (Placement to US Fund Allotment)”.

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

EXHIBITS

Exhibit Number Description
99.1 Immuron Completes A$5.1M Private Placement to US Fund
99.2 Appendix 3B
99.3 Section 708A Notice Disclosure

Field: Page; Sequence: 2

Field: /Page

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMMURON LIMITED
Date: March 16,
2018 By: /s/
Peter Vaughan
Peter Vaughan
Joint Chief Financial Officer

Field: Page; Sequence: 3; Options: Last

Field: /Page